[Transcatheter aortic valve implantation: Present and development trend]

Area of Science:

• Cardiovascular Medicine
• Interventional Cardiology
• Biomedical Engineering

Background:

• Severe aortic stenosis guidelines recommend surgical aortic valve replacement (SAVR) as the gold standard.
• Transcatheter aortic valve implantation (TAVI) is increasingly utilized for patients at high or prohibitive risk for SAVR.
• Medical companies, including those in China, are actively developing advanced TAVI devices.

Purpose of the Study:

• To evaluate the current status and future potential of transcatheter aortic valve implantation (TAVI) as a treatment for aortic stenosis.
• To compare the efficacy and safety of TAVI with surgical aortic valve replacement (SAVR).
• To highlight recent advancements in TAVI technology and its growing adoption.

Main Methods:

• Review of current clinical guidelines and recent advancements in TAVI technology.
• Analysis of outcomes data for TAVI compared to SAVR in high-risk patient populations.
• Examination of the role of valve manufacturers in TAVI device development.

Main Results:

• TAVI is demonstrating remarkable results and improved complication control.
• TAVI is becoming a common treatment option for patients unsuitable for SAVR.
• Ongoing innovation is enhancing TAVI device performance and applicability.

Conclusions:

• Transcatheter aortic valve implantation (TAVI) shows a promising future in treating aortic stenosis.
• TAVI is expected to potentially substitute SAVR for aortic stenosis and possibly aortic regurgitation.
• Continued technological development is crucial for expanding TAVI's role in cardiovascular interventions.